MySocieti Contact us Family Portal
Menu
  • Home
  • About Societi
    • Who we are
    • Our Approach
    • Our Work
    • Societi Foundation Achievements (to date..!)
    • Partnerships
    • For Funders and Policy Makers
  • Kawasaki Disease
    • 26 January – International Kawasaki Disease Awareness Day 2026
    • 29 September 2025 – World Heart Day
    • THINK Kawasaki Disease
    • Q & A
    • Kawasaki Disease & Vaccines
    • Kawasaki Disease & Covid-19
  • For Families
    • Families Resources & Downloads
    • Societi Membership
    • My Societi
    • Family Resource Portal
    • Family Stories
    • Sharing Experiences of Kawasaki Disease
    • Raising Awareness
      • Why I do what I do….
      • GP Packs and Hospital Packs
    • Get involved in a medical training project!
    • Other Help and Support
    • Societi Kids
  • For Clinicians
    • Learning & Information Resources
    • Kawasaki Disease Management
    • Kawasaki Disease Research Links
    • Clinicians Q & A
  • Fundraising
    • Getting Started!
    • JustGiving
    • Fundraising Ideas
    • Societi’s Heart Heroes
      • Junior Fundraising Heroes
    • Our Fundraising Targets
    • Societi Active
    • Leave a gift in your Will
  • News
    • News & Blog
    • For media
    • Newsletters
  • KD-CAAP Clincial Trial
    • What is KD-CAAP?
    • Understanding the KD-CAAP Trial
    • KD-CAAP – Information for Families
    • KD-CAAP News
    • KD-CAAP Trial Centres – Where the trial will take place
    • KD-CAAP and Your Data
  • Societi Shop
  • Steering Group

Kawasaki Disease Research Links

Research Disciplines

Long term impacts

Sensorineural hearing loss in patients with Kawasaki Disease

Sun Young Park, MD, Young Hyun Kim, MD, Yeo Hyang Kim, MD, PhD, Myung Chul Hyun, MD, PhD, and Young Hwan Lee, MD, PhD

November 2015

This study indicates that sensorineural hearing loss in children with Kawasaki Disease might occur during treatment of the acute phase; this SNHL usually involves mild bilateral hearing loss and recovers naturally.

Cardiovascular status after Kawasaki Disease in the UK

V Shah,1 G Christov,2 T Mukasa,2 K S Brogan,1 A Wade,3 D Eleftheriou,1 M Levin,4 RM Tulloh,5 B Almeida,1 MJ Dillon,1 J Marek,2 N Klein,1 PA Brogan1

August 2015

This study examined circulating endothelial cells (CECs) years after Kawasaki Disease

Safety and efficacy of warfarin plus aspirin combination therapy for giant coronary artery aneurysm secondary to Kawasaki Disease: a meta-analysis.

Su D, Wang K, Qin S, Pang Y.

August 2014

This study compared the safety and efficacy of warfarin plus aspirin versus aspirin alone

Behaviour sequelae following acute Kawasaki Disease

Daniel Carlton-Conway, Raju Ahluwalia, Lucy Henry, Colin Michie, Louise Wood and Robert Tulloh

May 2005

Kawasaki disease is a systemic vasculitis and may affect cerebral function acutely. The aim of the present study was to measure a number of behaviour and social parameters within a cohort of Kawasaki disease patients.

Share this page

Basket

Make a donation

We rely on donations to help us carry out our work. Your generosity will make a huge impact in the fight against Kawasaki Disease. Please help if you can.

Societi provides Kawasaki Disease information which has been directed by our Scientific Advisory Board. We are unable to provide specific medical advice. You should always check with your medical professional for information and advice relating to your symptoms/condition.

Societi Foundation, the UK Foundation for Kawasaki Disease

Societi Foundation is a Registered Charity in England and Wales, No 1173755
Victoria Court, Holme Lane, Winthorpe, Newark, Nottinghamshire NG24 2NU

Copyright © Societi, the UK Foundation for Kawasaki Disease | All Rights reserved

Facebook @SocietiFoundation Twitter @Societi_UK_KD
  • Contact Us
  • Societi Foundation Policies